Cancer therapy with genetically-modified T cells for the treatment of melanoma

Journal of Gene Medicine

Volumn 14, Issue 6, 2012, Pages 400-404

  Lagisetty, Kiran H ^a   Morgan, Richard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Melanoma; Skin

Indexed keywords

CANCER TESTIS ANTIGEN; EPITOPE; MELAN A; MELANOCYTE PROTEIN PMEL 17; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MONOPHENOL MONOOXYGENASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; NY ESO 1 ANTIGEN; TUMOR ANTIGEN;

AMINO ACID SUBSTITUTION; CANCER REGRESSION; CELL ENGINEERING; COLORECTAL CANCER; DNA MODIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE ISOLATION; GENE TARGETING; GENE TRANSFER; GENETIC ENGINEERING; HEALTH CARE PERSONNEL; HLA SYSTEM; HUMAN; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE RECEPTOR GENE; TRANSGENIC MOUSE; TUMOR REGRESSION;

CLINICAL TRIALS AS TOPIC; GENE TRANSFER TECHNIQUES; GENES, T-CELL RECEPTOR; GENETIC ENGINEERING; GENETIC THERAPY; HUMANS; MELANOMA; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; SKIN; T-LYMPHOCYTES;

EID: 84862897602     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2636     Document Type: Review

References (25)

1. Alexandrescu DT, Ichim TE, Riordan NH, et al. Immunotherapy for melanoma: current status and perspectives. J Immunother 2010; 33: 570-590.
2. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17: 4550-4557.
3. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647.
4. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009; 100: 2014-2021.
5. Cormier JN, Abati A, Fetsch P, et al. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J Immunother 1998; 21: 27-31.
6. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
7. Wei X, Walia V, Lin JC, et al. Exome sequencing identifies GRIN2 A as frequently mutated in melanoma. Nat Genet 2011; 43: 442-446.
8. Johnson LA, Heemskerk B, Powell DJ Jr, et al. Gene transfer of tumour-reactive TCR confers both high avidity and tumour reactivity to nonreactive peripheral blood mononuclear cells and tumour-infiltrating lymphocytes. J Immunol 2006; 177: 6548-6559.
9. Clay TM, Custer MC, Sachs J, et al. Efficient transfer of a tumour antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumour reactivity. J Immunol 1999; 163: 507-513.
10. Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumour antigen by TCR gene transfer. Nat Immunol 2001; 2: 962-970.
11. Zhao Y, Bennett AD, Zheng Z, et al. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumour cell lines. J Immunol 2007; 179: 5845-5854.
12. Wu X, Li Y, Crise B, et al. Transcription start regions in the human genome are favoured targets for MLV integration. Science 2003; 300: 1749-1751.
13. Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther 2010; 18: 674-683.
14. Cohen CJ, Zhao Y, Zheng Z, et al. Enhanced antitumour activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 2006; 66: 8878-8886.
15. Kuball J, Dossett ML, Wolfl M, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007; 109: 2331-2338.
16. Robbins PF, Li YF, El-Gamil M, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 2008; 180: 6116-6131.
17. Scholten KB, Kramer D, Kueter EW, et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol 2006; 119: 135-145.
18. Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011; 19: 620-626.
19. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114: 535-546.
20. Robbins PF, Morgan RA, Feldman SA, et al. Tumour regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29: 917-924.
21. Suri A. Cancer testis antigens - their importance in immunotherapy and in the early detection of cancer. Expert Opin Biol Ther 2006; 6: 379-389.
22. Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-625.
23. Bendle GM, Linnemann C, Hooijkaas AI, et al. Lethal graft-vs.-host disease in mouse models of T cell receptor gene therapy. Nat Med 2010; 16: 565-570.
24. van Loenen MM, de Boer R, Amir AL, et al. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci USA 2010; 107: 10972-10977.
25. Rosenberg SA. Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol Ther 2010; 18: 1744-1745.